Berotralstat News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Berotralstat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Berotralstat Today - Breaking & Trending Today

Once-Daily Berotralstat Treatment for HAE Consistently Decreases Attack Occurrences

These new data from BioCryst, presented at AAAAI, suggest that patients treated with berotralstat may see substantial decreases in HAE attacks.
....

United States , Jonathan Bernstein , A Prospective Survey In Community Pharmacies , Bernstein Allergy Group Jonathan , University Of Cincinnati , Biocryst Pharmaceuticals Inc , American Academy Of Allergy , Bernstein Allergy Group , Cryst Pharmaceuticals , Berotralstat Prophylaxis Reduces , Rates Regardless , Baseline Attacks , Real World Outcomes , Berotralstat Regardless , Prior Prophylaxis , Real World Effectiveness , Inhibitor Deficiency , Hereditary Angioedema , Prospective Survey , Community Pharmacies , Long Term Prophylaxis , Berolife Study Interim Analysis ,

BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey

RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals to commercialize ORLADEYO® (berotralstat) in Turkey. “We continue our mission to make ORLADEYO available to as many patients living with hereditary angioedema around the world as possible by partnering with companies that have deep expertise in commercializing rare disease therapies. We are pleased t ....

United States , John Bluth , Charlie Gayer , Cem Zorlular , Biocryst Pharmaceuticals Inc , Biocryst Pharmaceuticals , Exchange Commission , Kim Pharmaceuticals , Cryst Pharmaceuticals , Er Kim Pharmaceuticals , Important Safety , Annual Report , Quarterly Reports , Current Reports , Global Markets , Hereditary Angioedema , Pediatric Patients , Rare Disease , Dr Kim ,

BioCryst Pharma Receives Approval Of ORLADEYO From Public Health Institute Of Chile

BioCryst Pharmaceuticals, Inc. (BCRX) announced Monday that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older. ....

Pleasant Grove , United States , South Korea , South Korean , Josh Damaro , Ron Desantis , Nature Energy , Kia Corp , Drug Administration , Hyundai Motor , Utah Based Nature , Chewable Colostrum , Childrens Chewable Colostrum Berry , Orange Creamsicle , Biocryst Pharmaceuticals , Biocryst Pharma , Pint Pharma ,

BioCryst Launches ORLADEYO™ (berotralstat) in Germany

RESEARCH TRIANGLE PARK, N.C., June 03, 2021 (GLOBE NEWSWIRE) BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that oral, once-daily ORLADEYO™ (berotralstat) is now available for patients with a prescription in Germany. ORLADEYO was approved by the European Medicines Agency (EMA) on April 30, 2021 for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. The full European Summary of Product Characteristics (SMPC) for ORLADEYO is availa ....

Biocryst Pharmaceuticals , European Medicines Agency , Uropean Summary Of Product Characteristics , Hereditary Angioedema , Pediatric Patients , Moral Therapy , European Union , Ongoing Development ,

Early Access to BioCryst's Berotralstat Granted for HAE Patients in France

Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France
News Provided By
Share This Article
For investors and media only
RESEARCH TRIANGLE PARK, N.C., March 11, 2021 (GLOBE NEWSWIRE) BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the French National Agency for Medicines and Health Products Safety (ANSM) has granted an Autorisation Temporaire d Utilisation de cohorte (cohort ATU), or Temporary Authorization for Use, for the use of berotralstat to prevent attacks of hereditary angioedema (HAE) in appropriate patients aged 12 and older.
This cohort ATU allows patients with HAE in France to receive treatment with berotralstat before the drug is granted marketing authorization by the European Commmission (EC). ....

United States , United Kingdom , John Bluth , Catherine Collier Kyroulis , Jon Stonehouse , Autorisation Temporaire , Health Products Safety , Preference Centre , French National Agency For Medicines , University Hospital Grenoble , Exchange Commission , Healthcare Pharmaceuticals Industry , Biocryst Pharmaceuticals , European Union , European Medicines Agency , Biocryst Pharmaceuticals Inc , Committee For Medicinal Products Human Use , French Code Of Public Health , Cryst Pharmaceuticals , French National Agency , Temporary Authorization , European Commmission , French Code , Public Health , Laurence Bouillet , Coordinating Reference Centre ,